Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor
Sodium-glucose transporter 2 (SGLT2) inhibitors were shown to decrease mortality from cardiovascular diseases in the EMPA-REG trial. However, the effects of empagliflozin (EMPA) for cardiac arrhythmia are not yet clarified. A total of 20 C57BL/6J mice were divided into four groups: (1) The control g...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/16/3606 |
id |
doaj-e4c575f07bf547678224fe5f3aca8afa |
---|---|
record_format |
Article |
spelling |
doaj-e4c575f07bf547678224fe5f3aca8afa2020-11-25T03:35:53ZengMDPI AGMolecules1420-30492020-08-01253606360610.3390/molecules25163606Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 InhibitorShih-Jie Jhuo0I-Hsin Liu1Wei-Chung Tsai2Te-Wu Chou3Yi-Hsiung Lin4Bin-Nan Wu5Kun-Tai Lee6Wen-Ter Lai7Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanGraduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanSodium-glucose transporter 2 (SGLT2) inhibitors were shown to decrease mortality from cardiovascular diseases in the EMPA-REG trial. However, the effects of empagliflozin (EMPA) for cardiac arrhythmia are not yet clarified. A total of 20 C57BL/6J mice were divided into four groups: (1) The control group were fed standard chow, (2) the metabolic syndrome (MS) group were fed a high-fat diet, (3) the empagliflozin (EMPA) group were fed a high-fat diet and empagliflozin 10 mg/kg daily, and (4) the glibenclamide (GLI) group were fed a high-fat diet and glibenclamide 0.6 mg/kg daily. All mice were sacrificed after 16 weeks of feeding. H9c2 cells were treated with adipocytokines from the pericardial and peripheral fat from the study groups. The delayed-rectifier potassium current (I<sub>K</sub>) and L-type calcium channel current (I<sub>Ca,L</sub>) were measured by the whole-cell patch clamp techniques. Adipocytokines from the peripheral and pericardial fat tissues of mice with MS could decrease the I<sub>K</sub> and increase the I<sub>Ca,L</sub> of cardiomyocytes. After treating adipocytokines from pericardial fat, the I<sub>K</sub> in the EMPA and GLI groups were significantly higher than that in the MS group. The I<sub>K</sub> of the EMPA group was also significantly higher than the GLI group. The I<sub>Ca,L</sub> of the EMPA and GLI groups were significantly decreased overload compared with that of the MS group. However, there was no significant difference of I<sub>K</sub> and I<sub>Ca,L</sub> among study groups after treating adipocytokines from peripheral fat. Adipocytokines from pericardial fat but not peripheral fat tissues after EMPA therapy attenuated the effects of I<sub>K</sub> decreasing and I<sub>Ca,L</sub> increasing in the MS cardiomyocytes, which may contribute to anti-arrhythmic mechanisms of sodium-glucose transporter 2 (SGLT2) inhibitors.https://www.mdpi.com/1420-3049/25/16/3606pericardial fatadipocytokinedelayed-rectifier potassium current<span style="font-variant: small-caps">l</span>-type calcium channel current |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shih-Jie Jhuo I-Hsin Liu Wei-Chung Tsai Te-Wu Chou Yi-Hsiung Lin Bin-Nan Wu Kun-Tai Lee Wen-Ter Lai |
spellingShingle |
Shih-Jie Jhuo I-Hsin Liu Wei-Chung Tsai Te-Wu Chou Yi-Hsiung Lin Bin-Nan Wu Kun-Tai Lee Wen-Ter Lai Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor Molecules pericardial fat adipocytokine delayed-rectifier potassium current <span style="font-variant: small-caps">l</span>-type calcium channel current |
author_facet |
Shih-Jie Jhuo I-Hsin Liu Wei-Chung Tsai Te-Wu Chou Yi-Hsiung Lin Bin-Nan Wu Kun-Tai Lee Wen-Ter Lai |
author_sort |
Shih-Jie Jhuo |
title |
Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor |
title_short |
Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor |
title_full |
Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor |
title_fullStr |
Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor |
title_full_unstemmed |
Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor |
title_sort |
effects of secretome from fat tissues on ion currents of cardiomyocyte modulated by sodium-glucose transporter 2 inhibitor |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2020-08-01 |
description |
Sodium-glucose transporter 2 (SGLT2) inhibitors were shown to decrease mortality from cardiovascular diseases in the EMPA-REG trial. However, the effects of empagliflozin (EMPA) for cardiac arrhythmia are not yet clarified. A total of 20 C57BL/6J mice were divided into four groups: (1) The control group were fed standard chow, (2) the metabolic syndrome (MS) group were fed a high-fat diet, (3) the empagliflozin (EMPA) group were fed a high-fat diet and empagliflozin 10 mg/kg daily, and (4) the glibenclamide (GLI) group were fed a high-fat diet and glibenclamide 0.6 mg/kg daily. All mice were sacrificed after 16 weeks of feeding. H9c2 cells were treated with adipocytokines from the pericardial and peripheral fat from the study groups. The delayed-rectifier potassium current (I<sub>K</sub>) and L-type calcium channel current (I<sub>Ca,L</sub>) were measured by the whole-cell patch clamp techniques. Adipocytokines from the peripheral and pericardial fat tissues of mice with MS could decrease the I<sub>K</sub> and increase the I<sub>Ca,L</sub> of cardiomyocytes. After treating adipocytokines from pericardial fat, the I<sub>K</sub> in the EMPA and GLI groups were significantly higher than that in the MS group. The I<sub>K</sub> of the EMPA group was also significantly higher than the GLI group. The I<sub>Ca,L</sub> of the EMPA and GLI groups were significantly decreased overload compared with that of the MS group. However, there was no significant difference of I<sub>K</sub> and I<sub>Ca,L</sub> among study groups after treating adipocytokines from peripheral fat. Adipocytokines from pericardial fat but not peripheral fat tissues after EMPA therapy attenuated the effects of I<sub>K</sub> decreasing and I<sub>Ca,L</sub> increasing in the MS cardiomyocytes, which may contribute to anti-arrhythmic mechanisms of sodium-glucose transporter 2 (SGLT2) inhibitors. |
topic |
pericardial fat adipocytokine delayed-rectifier potassium current <span style="font-variant: small-caps">l</span>-type calcium channel current |
url |
https://www.mdpi.com/1420-3049/25/16/3606 |
work_keys_str_mv |
AT shihjiejhuo effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor AT ihsinliu effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor AT weichungtsai effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor AT tewuchou effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor AT yihsiunglin effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor AT binnanwu effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor AT kuntailee effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor AT wenterlai effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor |
_version_ |
1724552591177678848 |